Cogniguard updated that the European Patent Examiner, informed the company about its intention to issue a Notice of Allowance for its patent application for treating various neurological disorders
Cogniguard Ltd., a clinical stage company that is developing noninvasive Vagal Nerve Stimulation (VNS) for the treatments for Alzheimer’s disease, Cognitive impairment and Epilepsy, updated that the European Patent Examiner, informed the company about its intention to issue a Notice of Allowance for its patent application for treating various neurological disorders using its synchronized nerve activation technology.
This is in continue to the United States Patent and Trademark Office (USPTO) Notice of Allowance issued a few months ago.
Cogniguard, one of ShizimXL’s portfolio companies, is conducting its R&D activities in Lodz, Poland is developing three applications:
- VStimTM – Non-invasive neuromodulation platform used to promote memory capabilities in healthy subjects.
- VGuardTM – Non-invasive neuromodulation therapy for AD to reduce or stop cognitive decline based on VstimTM platform.
- StimulEpTM – Non-invasive neuromodulation therapy to suppress or stop nightly epileptic seizures based on VstimTM platform.